Patents by Inventor Lynette A. Fouser
Lynette A. Fouser has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 8906375Abstract: The present application provides human antibodies and antigen binding fragments thereof that specifically bind to the human interleukin-22 (IL-22) and methods of using those antibodies, for example, in diagnosing, treating or preventing inflammatory disorders, autoimmune diseases, allergies, septic shock, infectious disorders, transplant rejection, cancer, and other immune system disorders.Type: GrantFiled: November 22, 2010Date of Patent: December 9, 2014Assignee: Wyeth LLCInventors: Lynette A. Fouser, Martin Hegen, Deborah P. Luxenberg, Margot O'Toole
-
Patent number: 8470993Abstract: The present application provides human antibodies and antigen binding fragments thereof that specifically bind to the human interleukin-22 (IL-22). The antibodies can act as antagonists of IL-22 activity, thereby modulating immune responses in general, and those mediated by IL-22 in particular. The disclosed compositions and methods may be used for example, in diagnosing, treating or preventing inflammatory disorders, autoimmune diseases, allergies, septic shock, infectious disorders, transplant rejection, cancer, and other immune system disorders.Type: GrantFiled: May 22, 2012Date of Patent: June 25, 2013Assignees: Wyeth LLC, MedImmune LimitedInventors: Davinder S. Gill, Jing Li, Geertruida M. Veldman, Lynette A. Fouser, Viia Valge-Archer, David C. Lowe, Caroline S. Russell, Suzanne E. Cohen, Albert G. Thom, Ralph R. Minter
-
Publication number: 20130005033Abstract: The present application provides human antibodies and antigen binding fragments thereof that specifically bind to the human interleukin-22 (IL-22). The antibodies can act as antagonists of IL-22 activity, thereby modulating immune responses in general, and those mediated by IL-22 in particular. The disclosed compositions and methods may be used for example, in diagnosing, treating or preventing inflammatory disorders, autoimmune diseases, allergies, septic shock, infectious disorders, transplant rejection, cancer, and other immune system disorders.Type: ApplicationFiled: May 22, 2012Publication date: January 3, 2013Applicants: Wyeth LLC, MedImmune LimitedInventors: Davinder S. Gill, Jing Li, Geertruida M. Veldman, Lynette A. Fouser, Viia Valge-Archer, David C. Lowe, Caroline S. Russell, Suzanne E. Cohen, Albert G. Thom, Ralf R. Minter
-
Patent number: 8187603Abstract: The present application provides human antibodies and antigen binding fragments thereof that specifically bind to the human interleukin-22 (IL-22). The antibodies can act as antagonists of IL-22 activity, thereby modulating immune responses in general, and those mediated by IL-22 in particular. The disclosed compositions and methods may be used for example, in diagnosing, treating or preventing inflammatory disorders, autoimmune diseases, allergies, septic shock, infectious disorders, transplant rejection, cancer, and other immune system disorders.Type: GrantFiled: May 29, 2009Date of Patent: May 29, 2012Assignees: Wyeth LLC, MedImmune LimitedInventors: Davinder S. Gill, Jing Li, Geertruida M. Veldman, Lynette A. Fouser, Viia Valge-Archer, David C. Lowe, Caroline S. Russell, Suzanne E. Cohen, Albert G. Thom, Ralph R. Minter
-
Patent number: 8182817Abstract: The present application provides human antibodies and antigen binding fragments thereof that specifically bind to the human interleukin-22 (IL-22). The antibodies can act as antagonists of IL-22 activity, thereby modulating immune responses in general, and those mediated by IL-22 in particular. The disclosed compositions and methods may be used for example, in diagnosing, treating or preventing inflammatory disorders, autoimmune diseases, allergies, septic shock, infectious disorders, transplant rejection, cancer, and other immune system disorders.Type: GrantFiled: January 29, 2010Date of Patent: May 22, 2012Assignees: Wyeth LLC, Medimmune LimitedInventors: Davinder S. Gill, Jing Li, Geertruida M. Veldman, Lynette A. Fouser, Viia Valge-Archer, David C. Lowe, Caroline S. Russell, Suzanne E. Cohen, Albert G. Thom, Ralph R. Minter
-
Publication number: 20110275790Abstract: The present application provides human antibodies and antigen binding fragments thereof that specifically bind to the human interleukin-22 (IL-22). The antibodies can act as antagonists of IL-22 activity, thereby modulating immune responses in general, and those mediated by IL-22 in particular. The disclosed compositions and methods may be used for example, in diagnosing, treating or preventing inflammatory disorders, autoimmune diseases, allergies, septic shock, infectious disorders, transplant rejection, cancer, and other immune system disorders.Type: ApplicationFiled: May 29, 2009Publication date: November 10, 2011Applicants: MEDIMMUNE LIMITED, WYETHInventors: DAVINDER S. GILL, JING LI, GEERTRUIDA M. VELDMAN, LYNETTE A. FOUSER, VIIA VALGE-ARCHER, DAVID C. LOWE, CAROLINE S. RUSSELL, SUZANNE E. COHEN, ALBERT G. THOM, RALPH R. MINTER
-
Patent number: 8048984Abstract: Novel human GIL-19/AE289 protein is disclosed which shows a high degree of homology to interleukin-10 (IL-10). Polynucleotides encoding such protein are also enclosed.Type: GrantFiled: December 1, 2008Date of Patent: November 1, 2011Assignee: Genetics Institute, LLCInventors: Kenneth Jacobs, Lynette Fouser, Vikki Spaulding, Dejun Xuan
-
Publication number: 20110262390Abstract: Inhibitors of IL-22 are disclosed as well as pharmaceutical compositions and methods of using same. The inhibitors include IL-22 antibodies and are useful for treating inflammatory disorders.Type: ApplicationFiled: May 23, 2011Publication date: October 27, 2011Applicant: Genetics Institute, LLCInventors: Kenneth Jacobs, Debra D. Pittman, Lynette Fouser, Vikki Spaulding, Dejun Xuan
-
Publication number: 20110212099Abstract: The present application provides methods of modulating immune responses by using IL-22 in combination with at least one of IL-17A, IL-17F, or IL-23 or by using an IL-22 antagonist, such as an antibody or a soluble receptor or a binding protein, in combination with an antagonist of at least one of IL-17A, IL-17F, or IL-23Type: ApplicationFiled: March 15, 2011Publication date: September 1, 2011Applicant: Wyeth LLCInventors: Spencer C. LIANG, Lynette A. Fouser, Margot O'Toole
-
Patent number: 7951372Abstract: Inhibitors of IL-22 are disclosed as well as pharmaceutical compositions and methods of using same. The inhibitors include IL-22 antibodies and are useful for treating inflammatory disorders.Type: GrantFiled: August 31, 2007Date of Patent: May 31, 2011Assignee: Wyeth LLCInventors: Kenneth Jacobs, Debra D. Pittman, Lynette Fouser, Vikki Spaulding, Dejun Xuan
-
Publication number: 20110091478Abstract: The present application provides human antibodies and antigen binding fragments thereof that specifically bind to the human interleukin-22 (IL-22) and methods of using those antibodies, for example, in diagnosing, treating or preventing inflammatory disorders, autoimmune diseases, allergies, septic shock, infectious disorders, transplant rejection, cancer, and other immune system disorders.Type: ApplicationFiled: November 22, 2010Publication date: April 21, 2011Applicant: Wyeth LLCInventors: Lynette A. Fouser, Martin Hegen, Deborah P. Luxenberg, Margot O'Toole
-
Patent number: 7901684Abstract: The present application provides human antibodies and antigen binding fragments thereof that specifically bind to the human interleukin-22 (IL-22). The antibodies can act as antagonists of IL-22 activity, thereby modulating immune responses in general, and those mediated by IL-22 in particular. The disclosed compositions and methods may be used for example, in diagnosing, treating or preventing inflammatory disorders, autoimmune diseases, allergies, septic shock, infectious disorders, transplant rejection, cancer, and other immune system disorders.Type: GrantFiled: February 20, 2007Date of Patent: March 8, 2011Assignees: Wyeth LLC, Medimmune LimitedInventors: Davinder S. Gill, Jing Li, Geertruida M. Veldman, Lynette A. Fouser, Viia Valge-Archer, David C. Lowe, Caroline S. Russell, Suzanne E. Cohen, Albert G. Thom, Ralph R. Minter
-
Patent number: 7846444Abstract: The present application provides human antibodies and antigen binding fragments thereof that specifically bind to the human interleukin-22 (IL-22) and methods of using those antibodies, for example, in diagnosing, treating or preventing inflammatory disorders, autoimmune diseases, allergies, septic shock, infectious disorders, transplant rejection, cancer, and other immune system disorders.Type: GrantFiled: May 29, 2009Date of Patent: December 7, 2010Assignee: Wyeth LLCInventors: Lynette Fouser, Margot O'Toole, Deborah P. Luxenberg, Martin Hegen
-
Publication number: 20100260767Abstract: Inhibitors of IL-22 are disclosed as well as pharmaceutical compositions and methods of using same. The inhibitors include IL-22 antibodies and are useful for treating inflammatory disorders.Type: ApplicationFiled: January 15, 2010Publication date: October 14, 2010Inventors: Kenneth Jacobs, Debra D. Pittman, Lynette Fouser, Vikki Spaulding, Dejun Xuan
-
Patent number: 7811567Abstract: The present application provides human antibodies and antigen binding fragments thereof that specifically bind to the human interleukin-22 (IL-22) and methods of using those antibodies, for example, in diagnosing, treating or preventing inflammatory disorders, autoimmune diseases, allergies, septic shock, infectious disorders, transplant rejection, cancer, and other immune system disorders.Type: GrantFiled: February 20, 2007Date of Patent: October 12, 2010Assignee: Wyeth LLCInventors: Lynette A. Fouser, Martin Hegen, Deborah P. Luxenberg, Margot O'Toole
-
Publication number: 20100184960Abstract: The present application provides human antibodies and antigen binding fragments thereof that specifically bind to the human interleukin-22 (IL-22). The antibodies can act as antagonists of IL-22 activity, thereby modulating immune responses in general, and those mediated by IL-22 in particular. The disclosed compositions and methods may be used for example, in diagnosing, treating or preventing inflammatory disorders, autoimmune diseases, allergies, septic shock, infectious disorders, transplant rejection, cancer, and other immune system disorders.Type: ApplicationFiled: January 29, 2010Publication date: July 22, 2010Applicants: Wyeth, MedImmune LimitedInventors: Davinder S. Gill, Jing Li, Geertruida M. Veldman, Lynette A. Fouser, Viia Valge-Archer, David C. Lowe, Caroline S. Russell, Suzanne E. Cohen, Albert G. Thom, Ralph R. Minter
-
Publication number: 20100015162Abstract: The present application provides human antibodies and antigen binding fragments thereof that specifically bind to the human interleukin-22 (IL-22) and methods of using those antibodies, for example, in diagnosing, treating or preventing inflammatory disorders, autoimmune diseases, allergies, septic shock, infectious disorders, transplant rejection, cancer, and other immune system disorders.Type: ApplicationFiled: May 29, 2009Publication date: January 21, 2010Applicant: WyethInventors: Lynette A. FOUSER, Martin Hegen, Deborah P. Luxenberg, Margot O'Toole
-
Patent number: 7638604Abstract: Antibodies and antigen-binding fragments thereof that bind interleukin-22 (IL-22), in particular, human IL-22, and their uses in regulating IL-22-associated immune responses are disclosed. The antibodies disclosed herein are useful in diagnosing, preventing, or treating IL-22-associated immune disorders, e.g., autoimmune disorders (e.g., arthritis).Type: GrantFiled: June 22, 2004Date of Patent: December 29, 2009Assignee: Genetics Institute, LLCInventors: Jing Li, Xiang-Yang Tan, Kathleen N. Tomkinson, Debra D. Pittman, Geertruida M. Veldman, Lynette Fouser
-
Publication number: 20090232809Abstract: The present invention provides novel isolated CRF2-13 polynucleotides and polypeptides encoded by the CRF2-13 polynucleotides. Also provided are the antibodies that immunospecifically bind to a CRF2-13 polypeptide or any derivative (including fusion derivative), variant, mutant or fragment of the CRF2-13 polypeptide, polynucleotide or antibody. The invention additionally provides methods in which the CRF2-13 polypeptide, polynucleotide and antibody are utilized in the detection and treatment of a broad range of pathological states, as well as to other uses.Type: ApplicationFiled: September 18, 2008Publication date: September 17, 2009Inventors: Wei Liu, Lynette Fouser, Vikki Spaulding
-
Publication number: 20090227772Abstract: Novel human GIL-19/AE289 protein is disclosed which shows a high degree of homology to interleukin-10 (IL-10). Polynucleotides encoding such protein are also enclosed.Type: ApplicationFiled: December 1, 2008Publication date: September 10, 2009Inventors: Kenneth Jacobs, Lynette Fouser, Vikki Spaulding, Dejun Xuan